Posted by Michael Wonder on 06 Feb 2022
Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction
4 February 2022 - PDUFA target action date set for 30 November 2022.
Cytokinetics today announced that the U.S. FDA has accepted and filed the company’s new drug application for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction.
